Novo Nordisk teams up with WeightWatchers in latest telehealth push
Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with…
Metabolic Disorders
-
-
Why can’t the US figure out weight loss drug prices?
“I'm in London, and I just paid for this damn fat drug I take. I said, it's not working. They…
-
Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug
Novo Nordisk has terminated a collaboration agreement with Hims & Hers, accusing the telehealth company of "failing to adhere to…
-
Madrigal poised to enter European MASH market after CHMP endorsement
Madrigal Pharmaceuticals has moved one step closer to marketing the first treatment for metabolic dysfunction-associated steatohepatitis (MASH) in Europe after…
-
Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes
Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients…
-
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m…
-
Echosens and Boehringer expand partnership for MASH diagnosis
Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in metabolic dysfunction-associated steatohepatitis (MASH) diagnosis and care.…
-
MHRA warns women using weight loss jabs must use effective contraception
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has warned that women using weight loss jabs must use effective…
-
FDA rejects Stealth Bio’s Barth syndrome treatment after 16.5-month review
The US Food and Drug Administration (FDA) has rejected Stealth BioTherapeutics’ elamipretide for the treatment of Barth syndrome after a…
-
Wegovy and Zepbound costs capped at $200 in new Evernorth programme
Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal with drugmakers Novo Nordisk and Eli…
